Dermatology (Skin)

Alexandria M. Brown; Wylie M. Masterson; Anisha B. Patel

doi:10.1007/978-3-031-00241-0_3

Dermatology (Skin)

Alexandria M. Brown, Wylie M. Masterson, Anisha B. Patel

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Immune checkpoint inhibitors (ICIs) are increasingly used in cancer therapy and can have unintended side effects affecting several organ systems. Immune-related cutaneous adverse events (irCAEs) are the most frequent and earliest toxicities to arise. The most common irCAEs include maculopapular/morbilliform rash, pruritus, eczematous dermatoses, urticaria, lichenoid reactions, psoriasiform eruptions, and vitiligo. Interestingly, irCAEs are associated with an improved tumor response rate and positive prognosis in melanoma patients. Most irCAEs are mild and reversible, but when severe, they can drastically affect quality of life and cancer treatment course. Treatment is still an active area of research and depends on the rash severity. Management options include observation, topical and systemic corticosteroids, and various biologic and immunomodulatory therapies. This chapter outlines the epidemiology, clinical characteristics, evaluation, and management of irCAEs following ICI treatment.

Original language	English (US)
Title of host publication	Managing Immunotherapy Related Organ Toxicities
Subtitle of host publication	A Practical Guide
Publisher	Springer International Publishing
Pages	29-58
Number of pages	30
ISBN (Electronic)	9783031002410
ISBN (Print)	9783031002403
DOIs	https://doi.org/10.1007/978-3-031-00241-0_3
State	Published - Jan 1 2022
Externally published	Yes

Keywords

CTLA-4 inhibitor
Cutaneous adverse events
Dermatologic toxicities
Immune checkpoint inhibitors
Immune-related cutaneous adverse events
PD-1 inhibitor
PD-L1 inhibitor

ASJC Scopus subject areas

General Medicine
General Immunology and Microbiology

Access to Document

10.1007/978-3-031-00241-0_3

Cite this

@inbook{497f37d69e7e4ff59facaf12e807c711,

title = "Dermatology (Skin)",

abstract = "Immune checkpoint inhibitors (ICIs) are increasingly used in cancer therapy and can have unintended side effects affecting several organ systems. Immune-related cutaneous adverse events (irCAEs) are the most frequent and earliest toxicities to arise. The most common irCAEs include maculopapular/morbilliform rash, pruritus, eczematous dermatoses, urticaria, lichenoid reactions, psoriasiform eruptions, and vitiligo. Interestingly, irCAEs are associated with an improved tumor response rate and positive prognosis in melanoma patients. Most irCAEs are mild and reversible, but when severe, they can drastically affect quality of life and cancer treatment course. Treatment is still an active area of research and depends on the rash severity. Management options include observation, topical and systemic corticosteroids, and various biologic and immunomodulatory therapies. This chapter outlines the epidemiology, clinical characteristics, evaluation, and management of irCAEs following ICI treatment.",

keywords = "CTLA-4 inhibitor, Cutaneous adverse events, Dermatologic toxicities, Immune checkpoint inhibitors, Immune-related cutaneous adverse events, PD-1 inhibitor, PD-L1 inhibitor",

author = "Brown, {Alexandria M.} and Masterson, {Wylie M.} and Patel, {Anisha B.}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-031-00241-0_3",

language = "English (US)",

isbn = "9783031002403",

pages = "29--58",

booktitle = "Managing Immunotherapy Related Organ Toxicities",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Dermatology (Skin)

AU - Brown, Alexandria M.

AU - Masterson, Wylie M.

AU - Patel, Anisha B.

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Immune checkpoint inhibitors (ICIs) are increasingly used in cancer therapy and can have unintended side effects affecting several organ systems. Immune-related cutaneous adverse events (irCAEs) are the most frequent and earliest toxicities to arise. The most common irCAEs include maculopapular/morbilliform rash, pruritus, eczematous dermatoses, urticaria, lichenoid reactions, psoriasiform eruptions, and vitiligo. Interestingly, irCAEs are associated with an improved tumor response rate and positive prognosis in melanoma patients. Most irCAEs are mild and reversible, but when severe, they can drastically affect quality of life and cancer treatment course. Treatment is still an active area of research and depends on the rash severity. Management options include observation, topical and systemic corticosteroids, and various biologic and immunomodulatory therapies. This chapter outlines the epidemiology, clinical characteristics, evaluation, and management of irCAEs following ICI treatment.

AB - Immune checkpoint inhibitors (ICIs) are increasingly used in cancer therapy and can have unintended side effects affecting several organ systems. Immune-related cutaneous adverse events (irCAEs) are the most frequent and earliest toxicities to arise. The most common irCAEs include maculopapular/morbilliform rash, pruritus, eczematous dermatoses, urticaria, lichenoid reactions, psoriasiform eruptions, and vitiligo. Interestingly, irCAEs are associated with an improved tumor response rate and positive prognosis in melanoma patients. Most irCAEs are mild and reversible, but when severe, they can drastically affect quality of life and cancer treatment course. Treatment is still an active area of research and depends on the rash severity. Management options include observation, topical and systemic corticosteroids, and various biologic and immunomodulatory therapies. This chapter outlines the epidemiology, clinical characteristics, evaluation, and management of irCAEs following ICI treatment.

KW - CTLA-4 inhibitor

KW - Cutaneous adverse events

KW - Dermatologic toxicities

KW - Immune checkpoint inhibitors

KW - Immune-related cutaneous adverse events

KW - PD-1 inhibitor

KW - PD-L1 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85163483215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85163483215&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-00241-0_3

DO - 10.1007/978-3-031-00241-0_3

M3 - Chapter

AN - SCOPUS:85163483215

SN - 9783031002403

SP - 29

EP - 58

BT - Managing Immunotherapy Related Organ Toxicities

PB - Springer International Publishing

ER -

Dermatology (Skin)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this